Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) rose 5.8% on Friday . The company traded as high as $3.04 and last traded at $2.93. Approximately 3,045,801 shares changed hands during trading, an increase of 75% from the average daily volume of 1,742,600 shares. The stock had previously closed at $2.77.

AVEO has been the topic of a number of research reports. initiated coverage on shares of AVEO Pharmaceuticals in a research note on Wednesday, November 15th. They set a “buy” rating and a $5.00 target price on the stock. B. Riley began coverage on shares of AVEO Pharmaceuticals in a report on Monday, November 13th. They set a “buy” rating and a $5.00 price target on the stock. Seaport Global Securities reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, BidaskClub lowered shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $4.05.

The stock has a market capitalization of $346.64, a price-to-earnings ratio of -4.13 and a beta of 1.14. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33.

AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. equities analysts expect that AVEO Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Several large investors have recently modified their holdings of AVEO. Vanguard Group Inc. lifted its holdings in shares of AVEO Pharmaceuticals by 48.6% during the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock worth $7,884,000 after purchasing an additional 1,162,232 shares during the period. EAM Investors LLC acquired a new position in AVEO Pharmaceuticals in the second quarter valued at $1,979,000. Fore Research & Management LP acquired a new position in AVEO Pharmaceuticals in the second quarter valued at $111,000. RA Capital Management LLC acquired a new position in AVEO Pharmaceuticals in the second quarter valued at $18,727,000. Finally, Rehmann Capital Advisory Group acquired a new position in AVEO Pharmaceuticals in the third quarter valued at $193,000. Institutional investors own 50.91% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/aveo-pharmaceuticals-aveo-stock-price-up-5-8/1814488.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.